Everyone who told you AbbVie (ABBV) was going to collapse after the Humira patent cliff was not lying to you. They were just reasoning correctly from bad assumptions, which is far more dangerous.
The bear thesis was airtight on paper: Humira generated $21 billion annually at its peak, biosimilars were coming, and no drug in the history of the pharmaceutical industry had ever been successfully replaced at that scale by the same company.
Every single one of those facts was true. The conclusion they led to was completely wrong.
AbbVie spent the better part of a decade building two successor drugs. Skyrizi, targeting the IL-23 pathway, and Rinvoq, a JAK1 inhibitor, were not backup plans. They were the plan.
In Q1 2026, Skyrizi posted $4.5 billion in sales, up 29.2% year over year. Rinvoq added another $2.1 billion, up 20.2%. Together, $6.6 billion in a single quarter. Humira at its absolute peak never did that. The replacement didn't just fill the hole; it dug a bigger foundation underneath it.
What the bears consistently underestimated is how AbbVie engineered the succession.
Most pharma companies replace a blockbuster by going after an adjacent indication with a similar mechanism. AbbVie went after entirely new disease categories.
Skyrizi is now rapidly becoming the market leader in ulcerative colitis and Crohn's disease, indications Humira never dominated.
Management has guided Skyrizi to $33 billion in annual sales by 2031, with patent protection running into the mid-2030s. No biosimilar filing is expected before 2030.
That’s not a turnaround story but a decade-long runway with the gates locked behind it.
The Q1 2026 earnings report, AbbVie's eighth consecutive beat on both revenue and earnings, also crystallized something that tends to get lost in the immunology excitement: neuroscience is quietly becoming a second engine.
The neuroscience segment hit $2.9 billion in Q1 alone, up 24.3% year over year, with Vraylar contributing $905 million and Vyalev on what management is calling a blockbuster trajectory.
Full-year neuroscience guidance sits at $12.6 billion.
Add Tavapadon, a Parkinson's drug awaiting FDA approval in Q3 2026 that management projects as a $5 billion-plus franchise, and you start to see a company that has structurally diversified while everyone was staring at the Humira cliff.
The debt does exist and deserves honest treatment. AbbVie carries roughly $52.3 billion in net debt, partly a legacy of its $10.1 billion ImmunoGen acquisition in late 2023 and the earlier $63 billion Allergan deal. The current ratio sits at 0.67, which is tight.
But free cash flow is projected to rise 54% in fiscal 2026 to $27.5 billion, and the net debt to EBITDA ratio is on track to compress from 2.4 times to 1.6 times within the year.
A company generating that kind of cash flow does not stay overleveraged for long. The math works itself out, and AbbVie's management has proven they understand that.
On valuation, the stock trades at roughly 15 times forward earnings against a pharma peer average closer to 18 to 20 times. Merck (MRK) and Johnson & Johnson (JNJ) both trade at 19 to 20 times with materially lower earnings growth rates.
AbbVie is guiding for EPS of $14.37 to $14.57 for full-year 2026, up approximately 43% from fiscal 2025, with consensus estimates for fiscal 2027 converging in the $16 to $17 range. Even a modest re-rating toward peer multiples implies a stock price well north of current levels.
The macro environment is cooperating, too; in a slow-growth, sticky-inflation world with GDP running at 1.6% annualized and core CPI still elevated, institutional money rotates toward exactly this profile: a large-cap defensive with a 3% dividend yield, accelerating earnings, and unit demand that is completely inelastic to economic cycles.
People with autoimmune disease do not stop their biologics because the Fed raised rates.
The dip, when it comes, is the entry. The conclusion the bears got so spectacularly wrong turned out to be the best advertisement AbbVie ever had.












